Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology

In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and their actual benefit for patients. By adopting “pleural mesothelioma” as our clinical model we...

Descripción completa

Detalles Bibliográficos
Autores principales: Meirson, Tomer, Nardone, Valerio, Pentimalli, Francesca, Markel, Gal, Bomze, David, D’Apolito, Maria, Correale, Pierpaolo, Giordano, Antonio, Pirtoli, Luigi, Porta, Camillo, Gray, Steven G, Mutti, Luciano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749371/
https://www.ncbi.nlm.nih.gov/pubmed/36514092
http://dx.doi.org/10.1186/s12967-022-03744-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749371/
https://www.ncbi.nlm.nih.gov/pubmed/36514092
http://dx.doi.org/10.1186/s12967-022-03744-6

Ejemplares similares